June 20, 2017Open Access

Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Among patients treated with DAA, SVR was associated with a considerable reduction in the risk of HCC. We did not find any evidence to suggest that DAAs promote HCC. However, in patients with SVR, the absolute risk of HCC remained high in patients with established cirrhosis. These patients should be considered for ongoing HCC surveillance.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Kanwal et al. (Tue,) studied this question.

synapsesocial.com/papers/69e0024cb28b234044e9c381 https://doi.org/https://doi.org/10.1053/j.gastro.2017.06.012

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection2016 · 63 citations
2A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C–Associated Liver Cirrhosis2013 · 233 citations
3Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications2016 · 538 citations
4Accuracy and completeness of mortality data in the Department of Veterans Affairs2006 · 543 citations
5Racial Differences in the Progression to Cirrhosis and Hepatocellular Carcinoma in HCV-Infected Veterans2014 · 93 citations

Me gusta

Guardar

Ver artículo completo